Quality of Life and Health Economic Measurements in Allergic Patients Treated With Immunotherapy

Grass pollen and house dust mites (HDM) are the most common allergens causing allergic rhino-conjunctivitis (RC) and/or asthma (A). Subcutaneous allergen specific immunotherapy (SCIT) reduces symptoms and use of medication. The purpose of SABAL is to assess the effect of SCIT on disease severity classifications in terms of number of days affected- and sick days on patients with grass pollen and/or HDM induced disease. These outcome measures will be gathered in one single measure: Quality Adjusted Life Years (QALY)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypersensitivity Asthma Bronchial Diseases Effects of Immunotherapy Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Quality of Life Respiratory Hypersensitivity Respiratory Tract Diseases Rhino-Conjunctivitis

Age range

16 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults (> 16 years) and allergic to grass pollen and/or house dust mites.

Exclusion criteria

Allergic patients who had been immunotherapy treated before.

Sponsors and collaborators

Lead sponsor

Aalborg University

Other

Registry information

Official study title

Health Economic Analyses of Treatment Strategies for Allergic Respiratory Diseases

Acronym: SABAL

Important dates

Study start: 2005
Primary completion: 2009
Study completion: 2011
First posted: Dec 6, 2011
Registry last updated: Dec 6, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed